SeaStar Medical Announces Receipt Of A Category B Coverage Letter From The U.S. CMS For The NEUTRALIZE-AKI Pivotal Trial Evaluating The Co's Selective Cytopheretic Device In Adults With Acute Kidney Injury
SeaStar Medical Announces Receipt Of A Category B Coverage Letter From The U.S. CMS For The NEUTRALIZE-AKI Pivotal Trial Evaluating The Co's Selective Cytopheretic Device In Adults With Acute Kidney Injury
Reimbursement expected to accelerate medical site activations and cover a portion of the Company's NEUTRALIZE-AKI trial costs
報銷將加速醫療網站激活並支付公司 NEUTRALIZE-AKI 試驗成本的一部分。
DENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces receipt of a Category B Coverage Letter from the U.S. Centers for Medicare & Medicaid Services (CMS) for the NEUTRALIZE-AKI pivotal trial evaluating the Company's Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). CMS will pay for certain expenses incurred by medical centers treating patients covered by Medicare or Medicaid who are enrolled in the trial, which will cover a portion of SeaStar Medical's trial-related costs. Specifically, SeaStar Medical's SCD itself, as well as related and routine items and services, are approved for the purposes of Medicare coverage.
美國醫療保險和醫療服務中心（CMS）已發出一封類別爲b的保險函，該機構已覈准SeaStar Medical Holding Corporation（納斯達克股票代碼：ICU）的新穎型解決方案用於治療急性腎損傷（AKI）的選擇性細胞浸潤器材（SCD）在 NEUTRALIZE-AKI 關鍵試驗中，同時對基於此次試驗的醫療中心產生的某些費用予以支付，該試驗與納入試驗的醫療保險和醫療服務人員的患者相關。具體而言，SeaStar Medical的SCD本身、相關和例行項目和服務均已得到醫療保險的核準。
譯文內容由第三人軟體翻譯。